REDWOOD CITY, Calif.--(BUSINESS WIRE)--Dermira, a development-stage biotechnology company focused on developing innovative medical dermatology products for dermatologists and their patients, announces the progress of three programs into five Phase 2, proof of concept, clinical trials. The programs include DRM01, a novel, sebum inhibitor for acne; DRM02, a unique PDE4 inhibitor for inflammatory skin diseases; and DRM04 for hyperhidrosis.
Help employers find you! Check out all the jobs and post your resume.
